Endpoints News
Legend's next act after Carvykti Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M Tue W Th F
2 June, 2026
LGBTQ+ LEADERSHIP IN 2026
LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.
top stories
1. Exclusive: Bipartisan group of lawmakers unveil new bill to restrict China biotech
2. Travere pays Everest $112M upfront to grow rare kidney disease pipeline
3. Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti
4. Roche details narrow failure of breast cancer pill trial
5. Celcuity aims for broad FDA approval after positive breast cancer readout
6.
news briefing
Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3
7. Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis
8. Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
9. Allen Institute launches $200M effort to turn brain atlas lessons into medicines
10. Praxis sinks on late-stage study fail for seizure pill, halts second trial
more stories
 
Karen Weintraub
.

Are biopharma deals with China "dangerous"? A bipartisan pair of Michigan lawmakers thinks so and has proposed a bill that would greatly restrict them. Max Bayer has our exclusive look here.

.
Karen Weintraub
Deputy Editor, Endpoints News
Rep. John Moolenaar (R-MI) (Lenin Nolly/Sipa USA/Sipa via AP Images)
1
by Max Bayer

A bi­par­ti­san group of Michi­gan law­mak­ers re­leased a new bill that could great­ly sti­fle the boom­ing cross-bor­der deals spree be­tween Chi­nese and Amer­i­can biotechs.

Rep...

Read full story
2
by Kyle LaHucik

Tra­vere Ther­a­peu­tics is en­list­ing the help of Chi­na-based Ever­est Med­i­cines to bol­ster its rare kid­ney dis­ease pipeline be­yond its ap­proved med­i­cine Filspari.

The San Diego...

Read full story
Ying Huang, Legend Biotech CEO
3
by Lei Lei Wu

Leg­end Biotech’s long-await­ed first show­ing of in vi­vo CAR-T da­ta is here, fu­el­ing mo­men­tum in the grow­ing field.

Leg­end re­port­ed re­sults Tues­day on 12 lym­phoma...

Read full story
The Endpoints 100: Despite all the turmoil, biotech is having a moment
A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.
4
by Elizabeth Cairns

Back in March, Roche re­vealed that the breast can­cer pill on which it had pinned bil­lion-dol­lar sales ex­pec­ta­tionshad failed in a piv­otal Phase 3...

Read full story
Celcuity at #ASCO2026 (Karen Weintraub for Endpoints News)
5
by Nicole DeFeudis

Cel­cu­ity said a com­bi­na­tion reg­i­men with its ex­per­i­men­tal drug geda­tolis­ib dou­bled pa­tients' like­li­hood of sur­vival with­out dis­ease pro­gres­sion or death in a late-stage breast can­cer...